Table 2: Follow-up of physical tests in treatment and non-treatment groups.
Supplemented group (SG) | Non-supplemented group (NG) | ||||||||
Variable | CTSG (n = 48) | ATSG (n = 67) | MFSG (n = 51) | CT (n = 52) | AT (n = 79) | MF (n = 48) | Statistical analysis | F | P |
Functional tests | |||||||||
FRT_A | 21.90 ± 5.84 | 24.13 ± 5.80 | 25.63 ± 5.96 | 23.54 ± 5.81 | 23.00 ± 6.44 | 26.30 ± 6.22 | Effect time-vitamin | 1.49 | 0.30 |
FRT_B | 31.39 ± 7.31 | 30.24 ± 6.39 | 33.18 ± 7.46 | 30.01 ± 6.82 | 31.19 ± 6.46 | 32.28 ± 6.17 | Interaction of 25 (OH)D | 2.13 | 0.07 |
TUG_A | 8.18 ± 1.65 | 7.42 ± 1.36 | 6.76 ± 0.85 | 8.32 ± 1.48 | 7.00 ± 1.08 | 6.52 ± 1.26 | Effect time-vitamin | 0.12 | 0.66 |
TUG_B | 7.47 ± 0.97** | 7.23 ± 1.39 | 6.61 ± 1.16¤ | 7.98 ± 1.19 | 6.85 ± 0.98¤¤ | 6.51 ± 1.24 | Interaction of 25 (OH)D | 0.82 | 0.05* |
UB_A | 20.83 ± 9.07 | 19.09 ± 10.50 | 24.86 ± 8.20 | 17.06 ± 11.06 | 22.21 ± 10.23 | 27.18 ± 7.09 | Effect time-vitamin | 0.03 | 0.33 |
UB_B | 21.40 ± 10.55 | 21.10 ± 9.06 | 25.76 ± 7.81¤ | 21.34 ± 9.61 | 22.44 ± 8.83 | 27.81 ± 6.83¤§ | Interaction of 25(OH)D | 1.88 | 0.03* |
HS_A | 12.27 ± 1.65 | 12.37 ± 3.15 | 12.65 ± 2.46 | 12.89 ± 2.23 | 12.09 ± 2.11 | 12.14 ± 2.73 | Effect time-vitamin | 1.22 | 0.96 |
HS_B | 12.36 ± 1.18 | 12.46 ± 1.14 | 13.43 ± 1.53¤§ | 12.86 ± 1.17 | 12.44 ± 1.48 | 12.68 ± 1.49 | Interaction of 25 (OH)D | 1.63 | < 0.001* |
CS_A | 11.85 ± 2.95 | 13.31 ± 2.91 | 14.37 ± 4.13 | 10.82 ± 2.16 | 14.03 ± 2.74 | 14.93 ± 2.80 | Effect time-vitamin | 1.32 | 0.55 |
CS_B | 12.00 ± 2.19 | 13.92 ± 3.83¤¤ | 14.95 ± 3.58¤ | 11.95 ± 2.21 | 14.86 ± 4.17¤¤ | 15.58 ± 3.40¤ | Interaction of 25(OH)D | 0.12 | 0.04* |
2MST_A | 69.83 ± 18.43 | 78.25 ± 14.81 | 81.93 ± 16.84 | 72.06 ± 12.36 | 80.47 ± 15.52 | 88.71 ± 15.50 | Effect time-vitamin | 4.26 | 0.02* |
2MST_B | 74.50 ± 12.80 | 81.65 ± 18.30¤¤ | 82.45 ± 12.71¤§ | 79.85 ± 17.51 | 89.13 ± 15.39¤¤ | 92.66 ± 16.62¤ | Interaction of 25 (OH)D | 0.35 | 0.02* |